The British Journal of Psychiatry (2006) 189: 309-316. doi: 10.1192/bjp.bp.105.018325
© 2006 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in BJP
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by RUHÉ, H. G.
Right arrow Articles by SCHENE, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by RUHÉ, H. G.
Right arrow Articles by SCHENE, A. H.

REVIEW ARTICLES

Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder

Systematic review

HENRICUS G. RUHÉ, MD, JOCHANAN HUYSER, MD, PhD, JAN A. SWINKELS, MD, PhD and AART H. SCHENE, MD, PhD

Program for Mood Disorders AMC/De Meren, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

Correspondence: Dr H.G. Ruhé, c/o Mrs M. Haages, Out-patient Department of Psychiatry A3-255.1, Academic Medical Centre, PO Box 22660,1100 DD Amsterdam, The Netherlands. Tel. +31 20 566 2088; fax.: +31 20 691 9139; e-mail: H.G.Ruhe{at}AMC.UvA.nl

Declaration of interest None.

Background Although selective serotonin reuptake inhibitors (SSRIs) are frequently used for major depressive disorder, only 50–60% of patients respond to a standard dose. For non-responders, dose escalation is often applied.

Aim To systematically review the evidence for dose escalation of SSRIs.

Method A systematic literature search in MEDLINE, EMBASE, CINAHL and PsycInfo was performed. Randomised controlled trials and meta-analyses investigating dose escalation of SSRIs were identified. Relevant articles were retrieved and critically appraised. Results were summarised in an evidence table. Pooling was not justified because of heterogeneity of the identified studies.

Results Eighttrue dose-escalation studies and three meta-analyses were identified. The available data provided no unequivocal base fordose escalation. Dose escalation before 4 weeks of treatment at a standard dose appeared to be ineffective.

Conclusions Dose escalation of SSRIs is equivocally supported by evidence of randomised controlled trials; methodological difficulties in the studies may account for this lack of evidence.


Related articles in BJP:

PETER TYRER
BJP 2006 189: 390. [Full Text]  



This article has been cited by other articles:


Home page
 Psychosom. Med.Home page
B. L. Rollman, B. H. Belnap, M. S. LeMenager, S. Mazumdar, H. C. Schulberg, and C. F. Reynolds III
The Bypassing the Blues Treatment Protocol: Stepped Collaborative Care for Treating Post-CABG Depression
Psychosom Med, February 1, 2009; 71(2): 217 - 230.
[Abstract] [Full Text] [PDF]

Home page
 Med Decis MakingHome page
R. A. Hansen, C. G. Moore, S. B. Dusetzina, B. I. Leinwand, G. Gartlehner, and B. N. Gaynes
Controlling for Drug Dose in Systematic Review and Meta-Analysis: A Case Study of the Effect of Antidepressant Dose
Med Decis Making, January 1, 2009; 29(1): 91 - 103.
[Abstract] [PDF]

Home page
 BMJHome page
M. Timonen and T. Liukkonen
Management of depression in adults
BMJ, February 23, 2008; 336(7641): 435 - 439.
[Full Text] [PDF]

Home page
 Evid. Based Ment. HealthHome page
S. Heres, W. Kissling, and S. Leucht
Review: little evidence to support dose escalation of selective serotonin reuptake inhibitors in non-responders
Evid. Based Ment. Health, May 1, 2007; 10(2): 46 - 46.
[Full Text] [PDF]